Vectura Share Discussion Threads

[fhmktg] 04/4/2017 00:03

Last day of the tax year today...I suspect we'll see some sales to lock in profits for the year?

[pooroldboy55] 03/4/2017 16:22

back to normal up am down pm!!!!!!!!!!!!!!
Do think if we keep above 150 its ok but under and could go all the back to the 130

[alexchry] 03/4/2017 15:57

Yes, good news, particularly as the launch was earlier than expected but the share price has dipped slightly, I would have hoped for a modest rise.

[carpadium] 03/4/2017 15:01

At last, Utibron now available in US.

[carpadium] 31/3/2017 07:54

Demonstrating the design complexities the generic competitor has to overcome...

[dontay] 30/3/2017 23:13

best1467, as stated in the news release... the reasons for refusal have not been made public and it's up to Mylan if they choose to do so. Its not so much the formulation of the drug that matters... it's the expiry of the patents for GSK's complex Discus device that delivers the drug which is important and which has opened up the field for a generic version. The Mylan device and VECs Gyrohaler device are the only generic ones to have received approval in the USA as replacements for the Discus device.

[best1467] 30/3/2017 18:03

Does anyone know the reason for the mylan decision,are the two generics closely matched.

[popper joe] 30/3/2017 10:18

SoundBuy, was that a statement or a question?

[soundbuy] 30/3/2017 09:42

Few placing bets on Hikma/VEC 1st to mkt.........

[dontay] 30/3/2017 09:31

There you go, a nice rapid turnaround.

[cashstrapped] 30/3/2017 08:56

Got my 150 - looks like this will end blue today

[alexchry] 30/3/2017 08:41

Diesel-yes, I agree, markets don't like uncertainty. Carpadium is right, the decision on Mylan may be good or may be bad news regarding VEC's generic Advair but the risk that it may be bad news seems to have unsettled some investors. I've never sold any SKP or VEC shares as I remain optimistic that things will turn out well in the long run so fingers crossed.

[diesel] 30/3/2017 08:20

Carp, that's the nature of investing, no matter how much research you do there are elements that come down to a'spin of the wheel'. Failure to get our drug through will be a blow and knock share price but how much will depend on market sentiment, there havnt been too many positives of late, so I would imagine a hefty drop, there again.....

[carpadium] 30/3/2017 08:14

Idiotic market reaction to Mylan's rejection. Could just as easily considered one competitor down, HIK/VEC generic version possibly now first to market.

[soundbuy] 30/3/2017 08:02

Ho hum.........

[alexchry] 29/3/2017 22:33

Dontay-what you say may be true of some pharma companies but it was not the case with SKP or with OXB when Flutiform and Trovax failed, both company's share prices took a very big knock, unfortunately I was an investor in both of them. The good news for SKP was that it was only the US that didn't approve Flutiform. I do think that you are right that the share price will get a big boost if VEC's generic gets the go-ahead but I also think a rejection will cause a significant drop in the share price

[dontay] 29/3/2017 22:14

Pharma companies share price is pretty much mainly based on the reality of the 'here and now' rather than on a 'future potential' that may or may not happen. That's because in many cases where pharma is concerned... experience has shown it quite often doesn't happen! It's only when it's confirmed when pharma takes off. IMO there is probably some, but not much of the generic advair potential priced in at the moment... so if anything DOES come of it... it will be a nice big bonus! Maybe even bigger than hoped for now that Mylan's offering has gone on the back burner! Also as Carpadium has quite rightly pointed out... America is all about politics at the moment and Mylan could well be a victim of a vindictive certain guy over there which has no bearing on VEC's situation whatsoever!

[alexchry] 29/3/2017 20:54

It is hard to know whether the Mylan generic rejection is good news or bad news. Of course, it will be good if VEC have the first generic Advair on the market but the worry is that the FDA will have similar concerns with VEC's generic. We may know more when and if Mylan release details of why the FDA declined to approve their generic version of Advair. As a long term investor in SKP, I lost a lot of money when Flutiform failed to get US approval, I just hope history isn't going to repeat itself.

[carpadium] 29/3/2017 20:19

There's no love lost between the US government and Mylan. There's plenty of press regarding their US tax avoidance ploys and overpricing of drugs. FDA rejection could well be in retaliation which in turn would favour approval of Hikma's version.
Here's hoping.

[richtea1701] 29/3/2017 12:58

Wants to shake out the weak - knows what's coming

[az4hr] 29/3/2017 12:10

this share is so bloody annoying irritates the life out of me